Multidrug-resistant gram-negative bacteria: Trends, risk factors, and treatments

Emergency Medicine

Volumn 41, Issue 11, 2009, Pages 2-

  Engel, Lee S ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 71449122634     PISSN: 00136654     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. American College of Physicians-American Society of Internal Medicine. Antibiotic resistance. American College of Physicians Web site. http://www.acponline.org/patients_families/diseases_conditions/antiobiotic_resistance. Published 2000. Accessed October 25, 2009.
2. World Health Organization. Antimicrobial resistance. Fact sheet 194. World Health Organization Web site. www.who.int/mediacentre/factsheets/fs194/en. Revised January 2002. Accessed October 25, 2009.
3. Volles DF, Branan TN. Antibiotics in the intensive care unit: focus on agents for resistant pathogens. Emerg Med Clin North Am. 2008;26(3):813-34, x
4. Shorr AF. Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. Crit Care Med. 2009;37(4):1463-1469.
5. Cunha BA. New uses for older antibiotics: nitrofurantoin, amikacin, colistin, polymyxin B, doxycycline, and minocycline revisited. Med Clin North Am. 2006;90(6):1089-1107.
6. Michalopoulos A, Falagas ME. Colistin and polymyxin B in critical care. Crit Care Clin. 2008;24(2):377-91, x.
7. Vergidis PI, Falagas ME. New antibiotic agents for bloodstream infections. Int J Antimicrob Agents. 2008;32(suppl 1):S60-S65.
8. Chemaly RF, Hanmod SS, Jiang Y, et al. Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution. Medicine (Baltimore). 2009;88(4):211-220.
9. Jamal W, Salama M, Dehrab N, et al. Role of tigecycline in the control of a carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit. J Hosp Infect. 2009;72(3):234-242.
10. Slama TG. Gram-negative antibiotic resistance: there is a price to pay. Crit Care. 2008;12(suppl 4):S4.
11. Giske CG, Monnet DL, Cars O, Carmeli Y; ReAct-Action on Antibiotic Resistance. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother. 2008;52(3):813-821.
12. Sostarich AM, Zolldann D, Haefner H, et al. Impact of multiresistance of gram-negative bacteria in bloodstream infection on mortality rates and length of stay. Infection. 2008;36(1):31-35.
13. Wright SW, Wrenn KD, Haynes M, Haas DW. Prevalence and risk factors for multidrug resistant uropathogens in ED patients. Am J Emerg Med. 2000;18(2):143-146.
14. Gaynes R, Edwards JR; National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005;41(6):848-854.
15. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32(8):470-485.
16. Rossi F, Baquero F, Hsueh PR, et al. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother. 2006;58(1):205-210.
17. Church DL. Major factors affecting the emergence and re-emergence of infectious diseases. Clin Lab Med. 2004; 24(3):559-586, v.
18. World Health Organization. Use of antimicrobials outside human medicine and resultant antimicrobial resistance in humans. http://www.who.int/mediacentre/factsheets/fs268/en. Accessed November 3, 2009.
19. Livermore DM. Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis. 2003;36(suppl 1):S11-S23.
20. Chopra I, Schofield C, Everett M, et al. Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statement. Lancet Infect Dis. 2008;8(2):133-139.
21. Friedmann R, Raveh D, Zartzer E, et al. Prospective evaluation of colonization with extended-spectrum beta-lactamase (ESBL)-producing enterobacteriaceae among patients at hospital admission and of subsequent colonization with ESBL-producing enterobacteriaceae among patients during hospitalization. Infect Control Hosp Epidemiol. 2009;30(6):534-542.
22. Chiang WC, Chen SY, Chien KL, et al. Predictive model of antimicrobial-resistant gram-negative bacteremia at the ED. Am J Emerg Med. 2007;25(6):597-607.
23. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9(4):228-236.
24. Caterino JM. Evaluation and management of geriatric infections in the emergency department. Emerg Med Clin North Am. 2008;26(2):319-343, viii.
25. Azap OK, Arslan H, Serefhanolu K, et al. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect. 2009 Aug 18. [Epub ahead of print]
26. Evans HL, Lefrak SN, Lyman J, et al. Cost of Gram-negative resistance. Crit Care Med. 2007;35(1):89-95.
27. McGowan JE Jr. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. Am J Med. 2006;119(6 suppl 1): S29-S36.
28. Looney WJ, Narita M, Mühlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis. 2009;9(5):312-323.
29. US Centers for Disease Control and Prevention. Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep. 2007;56(14):332-336.
30. Tapsall JW. Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins. Curr Opin Infect Dis. 2009;22(1):87-91.
31. O'Neill AJ. New antibacterial agents for treating infections caused by multi-drug resistant Gram-negative bacteria. Expert Opin Investig Drugs. 2008;17(3):297-302.